News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
Augurex to Exhibit and Sponsor Industry Lunch Seminar at the AMLI 2025 Annual Meeting
Vancouver, Canada – August 5, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced its participation in the Association of Medical Laboratory Immunologists (AMLI) 38th Annual Meeting, taking place August 14–17 at the Hyatt...
Augurex to Exhibit at ADLM 2025, July 27–31 in Chicago, Illinois
Vancouver, Canada – July 17, 2025 – Augurex Life Sciences today announced it will be exhibiting and presenting new data at ADLM 2025 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), taking place July 27–31 in Chicago, IL. As one of the world’s...
Augurex to attend and sponsor Ten Topics in Rheumatology 2025, July 3–4 in London, UK
Augurex to attend and sponsor Ten Topics in Rheumatology 2025, July 3–4 in London, UK. Showcasing biomarker-based diagnostics: JOINTstat® for rheumatoid arthritis and SPINEstat™, a first-in-class diagnostic for axial spondyloarthritis Vancouver, Canada – June 26, 2025...
Augurex to Sponsor the AS/axSpA Back Summit 2025 Hosted by the Canadian Spondyloarthritis Association (CSA)
Augurex to sponsor the AS/axSpA Back Summit 2025, hosted by the Canadian Spondyloarthritis Association (CSA) Featuring SPINEstat™, a Health Canada-approved, first-in-class diagnostic blood test for the early and accurate detection of axial spondyloarthritis (axSpA)....
Augurex to attend BIO 2025, June 16–19, in Boston, MA, the world’s largest biotechnology partnering event.
Augurex to attend BIO 2025, June 16–19, in Boston, MA, the world’s largest biotechnology partnering event. Showcasing biomarker-based diagnostics for rheumatoid arthritis and axial spondyloarthritis, including JOINTstat® and first-in-class SPINEstat™. Vancouver,...
Take a Pain Check Foundation features a new blog highlighting Augurex’s 14-3-3eta biomarker
Take a Pain Check Foundation features a new blog highlighting Augurex’s 14-3-3eta biomarker. The blog post explores how biomarkers improve diagnosis and personalized care in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Vancouver, Canada – June 5,...
Augurex to present a poster and share a second accepted abstract at EULAR 2025, June 11–14 in Barcelona.
Augurex to present a poster and share a second accepted abstract at EULAR 2025, taking place June 11–14 in Barcelona. New findings highlight the value of 14-3-3eta autoantibodies in improving early detection of axSpA, including in HLA-B27–negative patients. Vancouver,...
Augurex to participate in the SPARTAN 2025 Annual Meeting in Toronto, Canada
Augurex to participate in the SPARTAN 2025 Annual Meeting, taking place May 9–10 in Toronto, Canada. Featuring SPINEstat™, a Health Canada-approved, first-in-class blood test for the early diagnosis and monitoring of axial spondyloarthritis (axSpA). Vancouver, Canada...
Augurex to attend British Society for Rheumatology 2025 Annual Meeting in Manchester, UK
Augurex to attend British Society for Rheumatology 2025 Annual Meeting in Manchester, UK Highlighting biomarker-based diagnostic innovations for RA and axSpA Vancouver, Canada – April 25, 2025 – Augurex Life Sciences Corp., a leader in biomarker-based diagnostics for...
Augurex Achieves MDSAP Certification
Vancouver, BC – August 22, 2024 – Augurex Life Sciences Corp., a leader in biomarker-driven diagnostic solutions for the detection and management of autoimmune diseases, today announced its successful certification under the Medical Device Single Audit Program...
Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO
Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO Co-Founder and outgoing CEO Dr. Norma Biln to helm research...
Life Sciences BC Names Augurex 2024 Emerging Company of the Year
VANCOUVER, BC – Life Sciences BC (LSBC) is pleased to announce the recipients of the 26th Annual Life Sciences BC Awards presented by Farris. These awards recognize the exceptional achievements of individuals, companies, and organizations across British Columbia’s...
New Day Diagnostics Collaboration
Augurex and New Day Diagnostics Collaborate to Launch SPINEstat™, Revolutionizing Early Diagnosis and Management of Ankylosing Spondylitis Vancouver, BC, Canada and Knoxville, TN, USA, 30 May 2024 – Augurex and New Day Diagnostics are excited to announce their...
Augurex has received $5M in funding from PacifiCan
Government of Canada invests almost $14 million to drive innovation and economic growth in Vancouver.Today, the Honourable Mary Ng, Minister of Export Promotion, International Trade and Economic Development on behalf of the Honourable Harjit S. Sajjan, Minister of...
Leading health publications are sharing the 14-3-3η blood test as part of the standard of care
Practical Pain Management highlights the 14-3-3η blood test The 14-3-3η blood test has been highlighted for earlier, more accurate diagnosis of rheumatoid arthritis by Practical Pain Management (PPM), a trusted publication providing evidence-based strategies for the...
14-3-3η: How Joint Involvement “Spreads”
14-3-3η: A Critical Mass of Data A recent systematic literature review describes a substantive body of evidence for 14-3-3η's clinically important role along the whole continuum of rheumatoid arthritis and autoimmune patient care.Key Statements:14-3-3η helps to assess...
10 Years of Peer-Reviewed Studies Predicting and Informing the Prognosis Profile of Autoimmune Patients
Recent journal publications are fortifying the clinically important role of the 14-3-3η blood test along the whole continuum of RA and autoimmune patient care. From RA meta-analysis data through to 14-3-3η expression in juvenile idiopathic arthritis and secondary...
Serum 14-3-3η A Predictor Of Secondary Sjögren’s Syndrome In SLE
Do you have a patient with Systemic Lupus Erythematosus (SLE) that you suspect may also have Sjögren’s Syndrome (SS)? With shared clinical and serological features, overlapping SS with SLE is a comorbidity that is often challenging to identify to promptly assist...
Augurex to attend CCR East 2025
Augurex to attend CCR East 2025 and present new research on 14-3-3eta auto-antibodies as a diagnostic marker for axial spondyloarthritis (axSpA). Augurex will be exhibiting at booth #66, showcasing how the 14-3-3eta test aids in the diagnosis and monitoring of...
Augurex to Present New Data at Leading Rheumatology and Diagnostics Conferences in 2025
Vancouver, Canada – April 15, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that multiple scientific abstracts have been accepted for presentation at major international rheumatology and diagnostics conferences...
Augurex attends the TRS 2025 Annual Meeting
Vancouver, Canada – February 21, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced its participation in the Tennessee Rheumatology Society (TRS) 2025 Annual Meeting taking place from February 28 – March 1 in...
Augurex attends the Canadian Rheumatology Association (CRA) 2025 Annual Scientific Meeting
Vancouver, Canada – February 19, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, is pleased to announce its participation in the Canadian Rheumatology Association (CRA) 2025 Annual Scientific Meeting, taking place February 26 –...
Augurex Attending RheumNow Live 2025
Vancouver, Canada – February 3, 2025 – Augurex is excited to announce that it will attend the RheumNow Live 2025 conference, a premier event bringing together leading rheumatologists and researchers to discuss the latest advancements in rheumatic disease diagnostics,...
Augurex to Present Axial Spondyloarthritis Data and Exhibit at ACR Convergence 2024 in Washington, DC
Augurex will present new research on 14-3-3η auto-antibodies as a diagnostic marker for axial spondyloarthritis. Augurex will be exhibiting at booth #2540, showcasing its innovative diagnostic for rheumatoid arthritis and newly launched first-in-class diagnostic test...
Augurex to Present Research on Novel Diagnostic 14-3-3η Auto-Antibody Marker for Axial Spondyloarthritis at the Spondylo Congress in Ghent
Vancouver, Canada – August 20, 2024 – Augurex Life Sciences Corp. today announced that it will be presenting a scientific poster at the upcoming Spondylo Congress, taking place in Ghent, Belgium, from September 5th to 7th, 2024. Augurex’s poster, titled "Novel...
Augurex to Present Two Posters at ADLM 2024 in Chicago
Vancouver, Canada – July 26, 2024 – Augurex Life Sciences Corp. is pleased to announce that it will be presenting two posters at the upcoming Association for Diagnostic & Laboratory Medicine (ADLM 2024) in Chicago. The event will be held from July 28 to August 1,...
Augurex and Quidel at ACR
Augurex and Quidel are pleased to announce the launch of the JOINTstat® 14-3-3η RUO (research use only) ELISA. This new distribution arrangement will get 14-3-3η testing into the hands of more investigators worldwide, including key opinion leaders and pharmaceutical...
Home
Products
Science
About
News
Careers
Contact